Artiva Biotherapeutics, Inc. Investing Cash Flow
Artiva Biotherapeutics, Inc. (ARTV) reported Investing Cash Flow of $32.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $17.59M, a 16.75% decline year-over-year.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $15.32M, a 53.61% increase year-over-year.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $16.04M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $16.28M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $63.41M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$120.46M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$25.98M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.90M 10-Q · filed 2026-08-06 | $48.94M derived: sum of 3 quarters · filed 2026-08-06 | $65.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.32M 10-Q · filed 2026-05-08 | $31.36M derived: sum of 2 quarters · filed 2026-05-08 | $47.63M derived: sum of 3 quarters · filed 2026-05-08 | $68.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $32.32M derived: sum of 2 quarters · filed 2026-03-10 | $53.44M derived: sum of 3 quarters · filed 2026-08-06 | $63.41M 10-K · filed 2026-03-10 |
| 2025-09-30 | $16.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $37.40M derived: sum of 2 quarters · filed 2026-08-06 | $47.37M 10-Q · filed 2025-11-12 | $46.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $31.09M 10-Q · filed 2026-08-06 | $30.13M derived: sum of 3 quarters · filed 2026-08-06 | -$100.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.97M 10-Q · filed 2026-05-08 | $9.01M derived: sum of 2 quarters · filed 2026-05-08 | -$121.62M derived: sum of 3 quarters · filed 2026-05-08 | -$120.27M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$966.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$131.59M derived: sum of 2 quarters · filed 2026-03-10 | -$130.25M derived: sum of 3 quarters · filed 2026-03-10 | -$120.46M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$130.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$129.28M derived: sum of 2 quarters · filed 2025-11-12 | -$119.50M 10-Q · filed 2025-11-12 | -$122.17M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $11.13M 10-Q · filed 2025-08-06 | $8.46M derived: sum of 3 quarters · filed 2025-08-06 | $7.97M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $9.78M 10-Q · filed 2025-05-08 | $7.11M derived: sum of 2 quarters · filed 2025-05-08 | $6.62M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$3.16M derived: sum of 2 quarters · filed 2025-03-24 | -$25.98M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$23.31M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$22.81M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |